NCT00827775

Mechanisms and Treatment of Intradialytic Hypertension

Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: University of Texas Southwestern Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

1. To determine in a cross sectional case-controlled cohort study of 50 hemodialysis patients if blood pressure elevations with hemodialysis are associated with decreased endothelial cell function (measured by brachial artery flow mediated dilation and endothelial progenitor cell number), both of which are novel mechanistic markers in the causal pathway for detrimental cardiovascular outcomes; and 2. To determine if lowering blood pressure with carvedilol in 25 ESRD subjects with blood pressure elevations with hemodialysis can improve endothelial cell dysfunction as a surrogate mechanistic marker for improving cardiovascular outcomes.

Conditions

• Intradialytic Hypertension

Interventions

Type	Name	Description
DRUG	Carvedilol	Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid

Timeline

• Start date: 2009-06-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2009-01-23
• Last updated: 2020-11-03
• Results posted: 2020-11-03

Locations

3 sites across 1 country: United States